Eckert & Ziegler appeals against CBFA decision

Eckert & Ziegler Strahlen- und Medizintechnik AG / Legal Matter
Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Berlin, 29.5.2009 - Further to its press release of 28 April 2009, and on the request of the Belgian securities regulator (CBFA), Eckert & Ziegler (ISIN DE0005659700) publicly confirms that it will, next week, lodge an appeal with the Court of Appeal of Brussels against the decision of the CBFA ordering it to launch a mandatory public takeover bid on International Brachytherapy at EUR 3.47 per share.

Eckert & Ziegler will request from the Court a preliminary decision suspending the execution of the decision of the CBFA. In the event that the Court would rule against Eckert & Ziegler in such preliminary decision, the acceptance period of the mandatory public takeover bid would then have to start within 40 working days after such Court decision.  
Eckert & Ziegler maintains that it has not violated any rules and is determined to vigorously defend the position that no public takeover bid is required under applicable rules.

Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.de


29.05.2009  Financial News transmitted by DGAP

---

 
Language:     English
Issuer: Eckert & Ziegler Strahlen- und Medizintechnik AG               Robert-Rössle-Str.10
              13125 Berlin
              Deutschland
Phone:        49 30 941084138
Fax:          49 30 941084112
E-mail:       karolin.riehle@ezag.de
Internet:     www.ezag.de
ISIN:         DE0005659700, ISIN DE0005659700
WKN:          565970, ISIN DE000A0L1L69
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin, München, Hamburg, Düsseldorf  
End of News DGAP News-Service  

---